182 related articles for article (PubMed ID: 12024000)
1. Prophylactic oophorectomy to reduce the risk of ovarian and breast cancer in carriers of BRCA mutations.
Haber D
N Engl J Med; 2002 May; 346(21):1660-2. PubMed ID: 12024000
[No Abstract] [Full Text] [Related]
2. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
Kauff ND; Satagopan JM; Robson ME; Scheuer L; Hensley M; Hudis CA; Ellis NA; Boyd J; Borgen PI; Barakat RR; Norton L; Castiel M; Nafa K; Offit K
N Engl J Med; 2002 May; 346(21):1609-15. PubMed ID: 12023992
[TBL] [Abstract][Full Text] [Related]
3. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
Rebbeck TR; Lynch HT; Neuhausen SL; Narod SA; Van't Veer L; Garber JE; Evans G; Isaacs C; Daly MB; Matloff E; Olopade OI; Weber BL;
N Engl J Med; 2002 May; 346(21):1616-22. PubMed ID: 12023993
[TBL] [Abstract][Full Text] [Related]
4. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
5. Oophorectomy in carriers of BRCA mutations.
Whitfield GA
N Engl J Med; 2002 Sep; 347(13):1037-40; author reply 1037-40. PubMed ID: 12353513
[No Abstract] [Full Text] [Related]
6. Risk-reducing salpingo-oophorectomy for BRCA mutation carriers.
Haldar K; Crawford R
Maturitas; 2010 Nov; 67(3):290. PubMed ID: 20869823
[No Abstract] [Full Text] [Related]
7. Prophylactic oophorectomy in women at increased cancer risk.
Domchek SM; Rebbeck TR
Curr Opin Obstet Gynecol; 2007 Feb; 19(1):27-30. PubMed ID: 17218848
[TBL] [Abstract][Full Text] [Related]
8. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up.
Olivier RI; van Beurden M; Lubsen MA; Rookus MA; Mooij TM; van de Vijver MJ; van't Veer LJ
Br J Cancer; 2004 Apr; 90(8):1492-7. PubMed ID: 15083174
[TBL] [Abstract][Full Text] [Related]
10. Oophorectomy in carriers of BRCA mutations.
Peshkin BN; DeMarco TA; Schwartz MD
N Engl J Med; 2002 Sep; 347(13):1037-40; author reply 1037-40. PubMed ID: 12353511
[No Abstract] [Full Text] [Related]
11. Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers.
Rhiem K; Foth D; Wappenschmidt B; Gevensleben H; Büttner R; Ulrich U; Schmutzler RK
Arch Gynecol Obstet; 2011 Mar; 283(3):623-7. PubMed ID: 20428881
[TBL] [Abstract][Full Text] [Related]
12. Surgical risk-reduction in carriers of BRCA mutations: where do we go from here?
Kauff ND; Barakat RR
Gynecol Oncol; 2004 May; 93(2):277-9. PubMed ID: 15099933
[No Abstract] [Full Text] [Related]
13. Oophorectomy in carriers of BRCA mutations.
Anderson WF; Brawley OW; Chang S
N Engl J Med; 2002 Sep; 347(13):1037-40; author reply 1037-40. PubMed ID: 12353512
[No Abstract] [Full Text] [Related]
14. Oral contraceptives, salpingo-oophorectomy and hormone replacement therapy in BRCA1-2 mutation carriers.
Biglia N; Mariani L; Ponzone R; Sismondi P
Maturitas; 2008 Jun; 60(2):71-7. PubMed ID: 18472232
[No Abstract] [Full Text] [Related]
15. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers.
Rebbeck TR
J Clin Oncol; 2000 Nov; 18(21 Suppl):100S-3S. PubMed ID: 11060335
[TBL] [Abstract][Full Text] [Related]
16. Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy.
Gadducci A; Biglia N; Cosio S; Sismondi P; Genazzani AR
Gynecol Endocrinol; 2010 Aug; 26(8):568-77. PubMed ID: 20632911
[TBL] [Abstract][Full Text] [Related]
17. CA125 screening after risk-reducing salpingo-oophorectomy: are the titers too high, or is it all just too much?
Bradford LS; Schorge JO
Menopause; 2011 Feb; 18(2):123-4. PubMed ID: 21191312
[No Abstract] [Full Text] [Related]
18. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.
Lamb JD; Garcia RL; Goff BA; Paley PJ; Swisher EM
Am J Obstet Gynecol; 2006 Jun; 194(6):1702-9. PubMed ID: 16731090
[TBL] [Abstract][Full Text] [Related]
19. Surveillance of survivors: follow-up after risk-reducing salpingo-oophorectomy in BRCA 1/2 mutation carriers.
Chapman JS; Powell CB; McLennan J; Crawford B; Mak J; Stewart N; Chen LM
Gynecol Oncol; 2011 Aug; 122(2):339-43. PubMed ID: 21531449
[TBL] [Abstract][Full Text] [Related]
20. Surgical risk reduction: prophylactic salpingo-oophorectomy and prophylactic mastectomy.
Dowdy SC; Stefanek M; Hartmann LC
Am J Obstet Gynecol; 2004 Oct; 191(4):1113-23. PubMed ID: 15507929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
